CSIRO, Imugene cooperate on bird flu vaccine project
05 February, 2004 by Graeme O'NeillCSIRO Livestock Industries and its animal health spin-off Imugene have begun a joint research project to develop a vaccine to protect chickens against the deadly new strain of avian influenza devastating poultry farms in Asia.
AGT soars on OTC obesity product hopes
04 February, 2004 by Melissa TrudingerThe share price of AGT Biosciences leapt nearly 15 per cent today, after the company announced it had filed patent applications for a series of 10 proteins that are likely to be suitable targets for the development of over-the-counter products to combat obesity.
Biotech: where Mars meets Venus
03 February, 2004 by Melissa TrudingerInvestors are from Mars and scientists are from Venus, according to one of the presenters at a biobusiness briefing in Melbourne this morning.
Biological waste specialist MediVac makes market debut
03 February, 2004 by Melissa TrudingerSydney-based medical waste equipment specialists MediVac (ASX:MDV) made its debut on the Australian Stock Exchange on Monday at AUD$0.30, 20 per cent above the IPO issue price of $0.25.
Antisense trial results seen as favourable
02 February, 2004 by Melissa TrudingerAntisense Therapeutics (ASX:ANP) has presented preliminary data from a Phase I clinical trial for its antisense multiple sclerosis drug ATL1102 at the Australian Neuroscience Society's annual conference last week.
Melbourne start-up Hexima applies to test GM cotton
02 February, 2004 by Graeme O'NeillMelbourne plant biotechnology company Hexima has applied to the Office of the Gene Technology Regulator to conduct a small field trial of transgenic cotton lines containing its novel protease-inhibitor genes.
MCRI deal with Quintiles to triple clinical trial activity
29 January, 2004 by Melissa TrudingerThe Murdoch Children's Research Institute (MCRI) in Melbourne has entered into an alliance with international clinical trials organisation Quintiles to bring international paediatric clinical trials to the institute's clinical trials group.
BioDiem lists on ASX after successful IPO
28 January, 2004 by Graeme O'NeillMelbourne pharmaceutical company BioDiem has listed on the Australian Stock Exchange (ASX:BDM), cashed up with AUD$12 million to fund its research and development program.
Gradipore touts technology's commercial potential
27 January, 2004 by Melissa TrudingerSydney-based bioseparations specialist Gradipore (ASX:GDP) claims to have successfully completed proof-of-principle studies demonstrating scale-up of its Gradiflow technology to commercial levels.
Research, biobusiness honoured in Australia Day awards
27 January, 2004 by Iain ScottLast week, ResMed's California-based chairman and CEO Dr Peter Farrell was in his usual stirring form at a Melbourne speech, referring to Australia as "Botswana" and the nation's flag as a "dog's breakfast". But perhaps he was just getting it all out of his system one last time -- on Monday, Farrell was named a Member of the Order of Australia (AM), one of the top gongs in the annual Australia Day honours
Starpharma has option to ditch PDF status
23 January, 2004 by Melissa TrudingerThe board of Melbourne nanotechnology company Starpharma (ASX:SPL) has been given the discretion to give up the company's pooled development fund (PDF) status if it becomes necessary.
Victory in sight on war against Johne's disease
23 January, 2004 by Graeme O'NeillIt's a Gollum of a pathogen: sneaky, tough, persistent, and able to remain hidden from its host's immune system as it goes about its nefarious business.
Gradipore names neighbour Minomic as distributor
22 January, 2004 by Melissa TrudingerSydney-based Gradipore (ASX:GDP) has entered into a non-exclusive distribution agreement with Sydney-based proteomics specialists Minomic to distribute its Gradiflow BF400 bioseparation instrument nationally.
New trial for Progen melanoma therapy
21 January, 2004 by Graeme O'NeillQueensland oncology drug-discovery company Progen Industries has begun a new Phase I/II clinical study of its lead anti-cancer compound PI-88 in patients with malignant melanoma.
CSL, Chiron move to Phase II hep C vaccine trial
20 January, 2004 by Graeme O'NeillThe hopes of hundreds of thousands of people around the world chronically infected with hepatitis C virus could be riding on an Australian clinical trial of a new, potentially life-saving vaccine being jointly developed by US-based Chiron Corporation and Melbourne pharmaceutical company CSL (ASX:CSL).
